Michael Zinda, EVP, Chief Science Officer at Repare Therapeutics Inc. (RPTX), sold 68,216 shares at $34.63 ($2.3M) on 2020-12-29, disclosed to the SEC on 2020-12-30.
Open-market sale of $2.3M RPTX by EVP, Chief Science Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $34.24 | 14,726 | $504K | 21.8% |
| 2 | $34.24 | 14,726 | $504K | 21.8% |
| 3 | $34.60 | 322 | $11K | 0.5% |
| 4 | $33.30 | 14,539 | $484K | 20.9% |
| 5 | $33.30 | 14,539 | $484K | 20.9% |
| 6 | $34.63 | 4,207 |
| $146K |
| 6.3% |
| 7 | $34.63 | 4,207 | $146K | 6.3% |
| 8 | $35.01 | 950 | $33K | 1.4% |
| Total | $33.90 avg | 68,216 | $2.3M | 100% |
| Filing → |
| RPTX | SELL | 2024-03-27 | $6K | — | Filing → |
| RPTX | SELL | 2023-06-09 | $189K | — | Filing → |
| RPTX | SELL | 2023-06-07 | $14K | — | Filing → |